Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?-Reference-Cited by-同舟云学术

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?

Published:2021-06-25 Issue:25 Volume:100 Page:e26388
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Moore Assaf,Bar Yael,Maurice-Dror Corinne,Finkel Inbar,Goldvaser Hadar,Dudnik Elizabeth,Goldstein Daniel A.,Gordon Noa,Billan Salem,Gutfeld Orit,Wolf Ido,Popovtzer Aron

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference49 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Thyroid carcinoma;Weber;Curr Opin Oncol,2006

3. Biologic and clinical perspectives on thyroid cancer;Fagin;N Engl J Med,2016

4. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer;Schlumberger;N Engl J Med,2015

5. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial;Brose;Lancet (London, England),2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas;Genes;2024-03-21

2. Comparative Cyto-Histological Genetic Profile in a Series of Differentiated Thyroid Carcinomas;Diagnostics;2024-01-27

3. Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors;Frontiers in Endocrinology;2023-10-05

4. Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma;Cancer Investigation;2023-03-01

5. Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective;Cancer Management and Research;2022-10